Illinois 2023-2024 Regular Session

Illinois House Bill HB3631 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1		-	Public Act 103-0453
2	1		HB3631 EnrolledLRB103 30054 BMS 56477 b HB3631 Enrolled LRB103 30054 BMS 56477 b
3	2		HB3631 Enrolled LRB103 30054 BMS 56477 b
4		-	AN ACT concerning regulation.
5		-	Be it enacted by the People of the State of Illinois,
6		-	represented in the General Assembly:
7		-	Section 5. The Illinois Insurance Code is amended by
8		-	changing Section 513b1 as follows:
9		-	(215 ILCS 5/513b1)
10		-	Sec. 513b1. Pharmacy benefit manager contracts.
11		-	(a) As used in this Section:
12		-	"340B drug discount program" means the program established
13		-	under Section 340B of the federal Public Health Service Act,
14		-	42 U.S.C. 256b.
15		-	"340B entity" means a covered entity as defined in 42
16		-	U.S.C. 256b(a)(4) authorized to participate in the 340B drug
17		-	discount program.
18		-	"340B pharmacy" means any pharmacy used to dispense 340B
19		-	drugs for a covered entity, whether entity-owned or external.
20		-	"Biological product" has the meaning ascribed to that term
21		-	in Section 19.5 of the Pharmacy Practice Act.
22		-	"Maximum allowable cost" means the maximum amount that a
23		-	pharmacy benefit manager will reimburse a pharmacy for the
24		-	cost of a drug.
25		-	"Maximum allowable cost list" means a list of drugs for
26		-	which a maximum allowable cost has been established by a
	3	+	1 AN ACT concerning regulation.
	4	+	2 Be it enacted by the People of the State of Illinois,
	5	+	3 represented in the General Assembly:
	6	+	4 Section 5. The Illinois Insurance Code is amended by
	7	+	5 changing Section 513b1 as follows:
	8	+	6 (215 ILCS 5/513b1)
	9	+	7 Sec. 513b1. Pharmacy benefit manager contracts.
	10	+	8 (a) As used in this Section:
	11	+	9 "340B drug discount program" means the program established
	12	+	10 under Section 340B of the federal Public Health Service Act,
	13	+	11 42 U.S.C. 256b.
	14	+	12 "340B entity" means a covered entity as defined in 42
	15	+	13 U.S.C. 256b(a)(4) authorized to participate in the 340B drug
	16	+	14 discount program.
	17	+	15 "340B pharmacy" means any pharmacy used to dispense 340B
	18	+	16 drugs for a covered entity, whether entity-owned or external.
	19	+	17 "Biological product" has the meaning ascribed to that term
	20	+	18 in Section 19.5 of the Pharmacy Practice Act.
	21	+	19 "Maximum allowable cost" means the maximum amount that a
	22	+	20 pharmacy benefit manager will reimburse a pharmacy for the
	23	+	21 cost of a drug.
	24	+	22 "Maximum allowable cost list" means a list of drugs for
	25	+	23 which a maximum allowable cost has been established by a
27	26
28	27
29	28
30	29		HB3631 Enrolled LRB103 30054 BMS 56477 b
31	30
32	31
33		-	pharmacy benefit manager.
34		-	"Pharmacy benefit manager" means a person, business, or
35		-	entity, including a wholly or partially owned or controlled
36		-	subsidiary of a pharmacy benefit manager, that provides claims
37		-	processing services or other prescription drug or device
38		-	services, or both, for health benefit plans.
39		-	"Retail price" means the price an individual without
40		-	prescription drug coverage would pay at a retail pharmacy, not
41		-	including a pharmacist dispensing fee.
42		-	"Third-party payer" means any entity that pays for
43		-	prescription drugs on behalf of a patient other than a health
44		-	care provider or sponsor of a plan subject to regulation under
45		-	Medicare Part D, 42 U.S.C. 1395w-101, et seq.
46		-	(b) A contract between a health insurer and a pharmacy
47		-	benefit manager must require that the pharmacy benefit
48		-	manager:
49		-	(1) Update maximum allowable cost pricing information
50		-	at least every 7 calendar days.
51		-	(2) Maintain a process that will, in a timely manner,
52		-	eliminate drugs from maximum allowable cost lists or
53		-	modify drug prices to remain consistent with changes in
54		-	pricing data used in formulating maximum allowable cost
55		-	prices and product availability.
56		-	(3) Provide access to its maximum allowable cost list
57		-	to each pharmacy or pharmacy services administrative
58		-	organization subject to the maximum allowable cost list.
	32	+	HB3631 Enrolled- 2 -LRB103 30054 BMS 56477 b HB3631 Enrolled - 2 - LRB103 30054 BMS 56477 b
	33	+	HB3631 Enrolled - 2 - LRB103 30054 BMS 56477 b
	34	+	1 pharmacy benefit manager.
	35	+	2 "Pharmacy benefit manager" means a person, business, or
	36	+	3 entity, including a wholly or partially owned or controlled
	37	+	4 subsidiary of a pharmacy benefit manager, that provides claims
	38	+	5 processing services or other prescription drug or device
	39	+	6 services, or both, for health benefit plans.
	40	+	7 "Retail price" means the price an individual without
	41	+	8 prescription drug coverage would pay at a retail pharmacy, not
	42	+	9 including a pharmacist dispensing fee.
	43	+	10 "Third-party payer" means any entity that pays for
	44	+	11 prescription drugs on behalf of a patient other than a health
	45	+	12 care provider or sponsor of a plan subject to regulation under
	46	+	13 Medicare Part D, 42 U.S.C. 1395w-101, et seq.
	47	+	14 (b) A contract between a health insurer and a pharmacy
	48	+	15 benefit manager must require that the pharmacy benefit
	49	+	16 manager:
	50	+	17 (1) Update maximum allowable cost pricing information
	51	+	18 at least every 7 calendar days.
	52	+	19 (2) Maintain a process that will, in a timely manner,
	53	+	20 eliminate drugs from maximum allowable cost lists or
	54	+	21 modify drug prices to remain consistent with changes in
	55	+	22 pricing data used in formulating maximum allowable cost
	56	+	23 prices and product availability.
	57	+	24 (3) Provide access to its maximum allowable cost list
	58	+	25 to each pharmacy or pharmacy services administrative
	59	+	26 organization subject to the maximum allowable cost list.
59	60
60	61
61		-	Access may include a real-time pharmacy website portal to
62		-	be able to view the maximum allowable cost list. As used in
63		-	this Section, "pharmacy services administrative
64		-	organization" means an entity operating within the State
65		-	that contracts with independent pharmacies to conduct
66		-	business on their behalf with third-party payers. A
67		-	pharmacy services administrative organization may provide
68		-	administrative services to pharmacies and negotiate and
69		-	enter into contracts with third-party payers or pharmacy
70		-	benefit managers on behalf of pharmacies.
71		-	(4) Provide a process by which a contracted pharmacy
72		-	can appeal the provider's reimbursement for a drug subject
73		-	to maximum allowable cost pricing. The appeals process
74		-	must, at a minimum, include the following:
75		-	(A) A requirement that a contracted pharmacy has
76		-	14 calendar days after the applicable fill date to
77		-	appeal a maximum allowable cost if the reimbursement
78		-	for the drug is less than the net amount that the
79		-	network provider paid to the supplier of the drug.
80		-	(B) A requirement that a pharmacy benefit manager
81		-	must respond to a challenge within 14 calendar days of
82		-	the contracted pharmacy making the claim for which the
83		-	appeal has been submitted.
84		-	(C) A telephone number and e-mail address or
85		-	website to network providers, at which the provider
86		-	can contact the pharmacy benefit manager to process
87	62
88	63
89		-	and submit an appeal.
90		-	(D) A requirement that, if an appeal is denied,
91		-	the pharmacy benefit manager must provide the reason
92		-	for the denial and the name and the national drug code
93		-	number from national or regional wholesalers.
94		-	(E) A requirement that, if an appeal is sustained,
95		-	the pharmacy benefit manager must make an adjustment
96		-	in the drug price effective the date the challenge is
97		-	resolved and make the adjustment applicable to all
98		-	similarly situated network pharmacy providers, as
99		-	determined by the managed care organization or
100		-	pharmacy benefit manager.
101		-	(5) Allow a plan sponsor contracting with a pharmacy
102		-	benefit manager an annual right to audit compliance with
103		-	the terms of the contract by the pharmacy benefit manager,
104		-	including, but not limited to, full disclosure of any and
105		-	all rebate amounts secured, whether product specific or
106		-	generalized rebates, that were provided to the pharmacy
107		-	benefit manager by a pharmaceutical manufacturer.
108		-	(6) Allow a plan sponsor contracting with a pharmacy
109		-	benefit manager to request that the pharmacy benefit
110		-	manager disclose the actual amounts paid by the pharmacy
111		-	benefit manager to the pharmacy.
112		-	(7) Provide notice to the party contracting with the
113		-	pharmacy benefit manager of any consideration that the
114		-	pharmacy benefit manager receives from the manufacturer
	64	+
	65	+	HB3631 Enrolled - 2 - LRB103 30054 BMS 56477 b
115	66
116	67
117		-	for dispense as written prescriptions once a generic or
118		-	biologically similar product becomes available.
119		-	(c) In order to place a particular prescription drug on a
120		-	maximum allowable cost list, the pharmacy benefit manager
121		-	must, at a minimum, ensure that:
122		-	(1) if the drug is a generically equivalent drug, it
123		-	is listed as therapeutically equivalent and
124		-	pharmaceutically equivalent "A" or "B" rated in the United
125		-	States Food and Drug Administration's most recent version
126		-	of the "Orange Book" or have an NR or NA rating by
127		-	Medi-Span, Gold Standard, or a similar rating by a
128		-	nationally recognized reference;
129		-	(2) the drug is available for purchase by each
130		-	pharmacy in the State from national or regional
131		-	wholesalers operating in Illinois; and
132		-	(3) the drug is not obsolete.
133		-	(d) A pharmacy benefit manager is prohibited from limiting
134		-	a pharmacist's ability to disclose whether the cost-sharing
135		-	obligation exceeds the retail price for a covered prescription
136		-	drug, and the availability of a more affordable alternative
137		-	drug, if one is available in accordance with Section 42 of the
138		-	Pharmacy Practice Act.
139		-	(e) A health insurer or pharmacy benefit manager shall not
140		-	require an insured to make a payment for a prescription drug at
141		-	the point of sale in an amount that exceeds the lesser of:
142		-	(1) the applicable cost-sharing amount; or
	68	+	HB3631 Enrolled- 3 -LRB103 30054 BMS 56477 b HB3631 Enrolled - 3 - LRB103 30054 BMS 56477 b
	69	+	HB3631 Enrolled - 3 - LRB103 30054 BMS 56477 b
	70	+	1 Access may include a real-time pharmacy website portal to
	71	+	2 be able to view the maximum allowable cost list. As used in
	72	+	3 this Section, "pharmacy services administrative
	73	+	4 organization" means an entity operating within the State
	74	+	5 that contracts with independent pharmacies to conduct
	75	+	6 business on their behalf with third-party payers. A
	76	+	7 pharmacy services administrative organization may provide
	77	+	8 administrative services to pharmacies and negotiate and
	78	+	9 enter into contracts with third-party payers or pharmacy
	79	+	10 benefit managers on behalf of pharmacies.
	80	+	11 (4) Provide a process by which a contracted pharmacy
	81	+	12 can appeal the provider's reimbursement for a drug subject
	82	+	13 to maximum allowable cost pricing. The appeals process
	83	+	14 must, at a minimum, include the following:
	84	+	15 (A) A requirement that a contracted pharmacy has
	85	+	16 14 calendar days after the applicable fill date to
	86	+	17 appeal a maximum allowable cost if the reimbursement
	87	+	18 for the drug is less than the net amount that the
	88	+	19 network provider paid to the supplier of the drug.
	89	+	20 (B) A requirement that a pharmacy benefit manager
	90	+	21 must respond to a challenge within 14 calendar days of
	91	+	22 the contracted pharmacy making the claim for which the
	92	+	23 appeal has been submitted.
	93	+	24 (C) A telephone number and e-mail address or
	94	+	25 website to network providers, at which the provider
	95	+	26 can contact the pharmacy benefit manager to process
143	96
144	97
145		-	(2) the retail price of the drug in the absence of
146		-	prescription drug coverage.
147		-	(f) Unless required by law, a contract between a pharmacy
148		-	benefit manager or third-party payer and a 340B entity or 340B
149		-	pharmacy shall not contain any provision that:
150		-	(1) distinguishes between drugs purchased through the
151		-	340B drug discount program and other drugs when
152		-	determining reimbursement or reimbursement methodologies,
153		-	or contains otherwise less favorable payment terms or
154		-	reimbursement methodologies for 340B entities or 340B
155		-	pharmacies when compared to similarly situated non-340B
156		-	entities;
157		-	(2) imposes any fee, chargeback, or rate adjustment
158		-	that is not similarly imposed on similarly situated
159		-	pharmacies that are not 340B entities or 340B pharmacies;
160		-	(3) imposes any fee, chargeback, or rate adjustment
161		-	that exceeds the fee, chargeback, or rate adjustment that
162		-	is not similarly imposed on similarly situated pharmacies
163		-	that are not 340B entities or 340B pharmacies;
164		-	(4) prevents or interferes with an individual's choice
165		-	to receive a covered prescription drug from a 340B entity
166		-	or 340B pharmacy through any legally permissible means,
167		-	except that nothing in this paragraph shall prohibit the
168		-	establishment of differing copayments or other
169		-	cost-sharing amounts within the benefit plan for covered
170		-	persons who acquire covered prescription drugs from a
171	98
172	99
173		-	nonpreferred or nonparticipating provider;
174		-	(5) excludes a 340B entity or 340B pharmacy from a
175		-	pharmacy network on any basis that includes consideration
176		-	of whether the 340B entity or 340B pharmacy participates
177		-	in the 340B drug discount program;
178		-	(6) prevents a 340B entity or 340B pharmacy from using
179		-	a drug purchased under the 340B drug discount program; or
180		-	(7) any other provision that discriminates against a
181		-	340B entity or 340B pharmacy by treating the 340B entity
182		-	or 340B pharmacy differently than non-340B entities or
183		-	non-340B pharmacies for any reason relating to the
184		-	entity's participation in the 340B drug discount program.
185		-	As used in this subsection, "pharmacy benefit manager" and
186		-	"third-party payer" do not include pharmacy benefit managers
187		-	and third-party payers acting on behalf of a Medicaid program.
188		-	(g) A violation of this Section by a pharmacy benefit
189		-	manager constitutes an unfair or deceptive act or practice in
190		-	the business of insurance under Section 424.
191		-	(h) A provision that violates subsection (f) in a contract
192		-	between a pharmacy benefit manager or a third-party payer and
193		-	a 340B entity that is entered into, amended, or renewed after
194		-	July 1, 2022 shall be void and unenforceable.
195		-	(i)(1) A pharmacy benefit manager may not retaliate
196		-	against a pharmacist or pharmacy for disclosing information in
197		-	a court, in an administrative hearing, before a legislative
198		-	commission or committee, or in any other proceeding, if the
	100	+
	101	+	HB3631 Enrolled - 3 - LRB103 30054 BMS 56477 b
199	102
200	103
201		-	pharmacist or pharmacy has reasonable cause to believe that
202		-	the disclosed information is evidence of a violation of a
203		-	State or federal law, rule, or regulation.
204		-	(2) A pharmacy benefit manager may not retaliate against a
205		-	pharmacist or pharmacy for disclosing information to a
206		-	government or law enforcement agency, if the pharmacist or
207		-	pharmacy has reasonable cause to believe that the disclosed
208		-	information is evidence of a violation of a State or federal
209		-	law, rule, or regulation.
210		-	(3) A pharmacist or pharmacy shall make commercially
211		-	reasonable efforts to limit the disclosure of confidential and
212		-	proprietary information.
213		-	(4) Retaliatory actions against a pharmacy or pharmacist
214		-	include cancellation of, restriction of, or refusal to renew
215		-	or offer a contract to a pharmacy solely because the pharmacy
216		-	or pharmacist has:
217		-	(A) made disclosures of information that the
218		-	pharmacist or pharmacy has reasonable cause to believe is
219		-	evidence of a violation of a State or federal law, rule, or
220		-	regulation;
221		-	(B) filed complaints with the plan or pharmacy benefit
222		-	manager; or
223		-	(C) filed complaints against the plan or pharmacy
224		-	benefit manager with the Department.
225		-	(j) (i) This Section applies to contracts entered into or
226		-	renewed on or after July 1, 2022.
	104	+	HB3631 Enrolled- 4 -LRB103 30054 BMS 56477 b HB3631 Enrolled - 4 - LRB103 30054 BMS 56477 b
	105	+	HB3631 Enrolled - 4 - LRB103 30054 BMS 56477 b
	106	+	1 and submit an appeal.
	107	+	2 (D) A requirement that, if an appeal is denied,
	108	+	3 the pharmacy benefit manager must provide the reason
	109	+	4 for the denial and the name and the national drug code
	110	+	5 number from national or regional wholesalers.
	111	+	6 (E) A requirement that, if an appeal is sustained,
	112	+	7 the pharmacy benefit manager must make an adjustment
	113	+	8 in the drug price effective the date the challenge is
	114	+	9 resolved and make the adjustment applicable to all
	115	+	10 similarly situated network pharmacy providers, as
	116	+	11 determined by the managed care organization or
	117	+	12 pharmacy benefit manager.
	118	+	13 (5) Allow a plan sponsor contracting with a pharmacy
	119	+	14 benefit manager an annual right to audit compliance with
	120	+	15 the terms of the contract by the pharmacy benefit manager,
	121	+	16 including, but not limited to, full disclosure of any and
	122	+	17 all rebate amounts secured, whether product specific or
	123	+	18 generalized rebates, that were provided to the pharmacy
	124	+	19 benefit manager by a pharmaceutical manufacturer.
	125	+	20 (6) Allow a plan sponsor contracting with a pharmacy
	126	+	21 benefit manager to request that the pharmacy benefit
	127	+	22 manager disclose the actual amounts paid by the pharmacy
	128	+	23 benefit manager to the pharmacy.
	129	+	24 (7) Provide notice to the party contracting with the
	130	+	25 pharmacy benefit manager of any consideration that the
	131	+	26 pharmacy benefit manager receives from the manufacturer
227	132
228	133
229		-	(k) (j) This Section applies to any group or individual
230		-	policy of accident and health insurance or managed care plan
231		-	that provides coverage for prescription drugs and that is
232		-	amended, delivered, issued, or renewed on or after July 1,
233		-	2020.
234		-	(Source: P.A. 101-452, eff. 1-1-20; 102-778, eff. 7-1-22;
235		-	revised 8-19-22.)
	134	+
	135	+
	136	+
	137	+	HB3631 Enrolled - 4 - LRB103 30054 BMS 56477 b
	138	+
	139	+
	140	+	HB3631 Enrolled- 5 -LRB103 30054 BMS 56477 b HB3631 Enrolled - 5 - LRB103 30054 BMS 56477 b
	141	+	HB3631 Enrolled - 5 - LRB103 30054 BMS 56477 b
	142	+	1 for dispense as written prescriptions once a generic or
	143	+	2 biologically similar product becomes available.
	144	+	3 (c) In order to place a particular prescription drug on a
	145	+	4 maximum allowable cost list, the pharmacy benefit manager
	146	+	5 must, at a minimum, ensure that:
	147	+	6 (1) if the drug is a generically equivalent drug, it
	148	+	7 is listed as therapeutically equivalent and
	149	+	8 pharmaceutically equivalent "A" or "B" rated in the United
	150	+	9 States Food and Drug Administration's most recent version
	151	+	10 of the "Orange Book" or have an NR or NA rating by
	152	+	11 Medi-Span, Gold Standard, or a similar rating by a
	153	+	12 nationally recognized reference;
	154	+	13 (2) the drug is available for purchase by each
	155	+	14 pharmacy in the State from national or regional
	156	+	15 wholesalers operating in Illinois; and
	157	+	16 (3) the drug is not obsolete.
	158	+	17 (d) A pharmacy benefit manager is prohibited from limiting
	159	+	18 a pharmacist's ability to disclose whether the cost-sharing
	160	+	19 obligation exceeds the retail price for a covered prescription
	161	+	20 drug, and the availability of a more affordable alternative
	162	+	21 drug, if one is available in accordance with Section 42 of the
	163	+	22 Pharmacy Practice Act.
	164	+	23 (e) A health insurer or pharmacy benefit manager shall not
	165	+	24 require an insured to make a payment for a prescription drug at
	166	+	25 the point of sale in an amount that exceeds the lesser of:
	167	+	26 (1) the applicable cost-sharing amount; or
	168	+
	169	+
	170	+
	171	+
	172	+
	173	+	HB3631 Enrolled - 5 - LRB103 30054 BMS 56477 b
	174	+
	175	+
	176	+	HB3631 Enrolled- 6 -LRB103 30054 BMS 56477 b HB3631 Enrolled - 6 - LRB103 30054 BMS 56477 b
	177	+	HB3631 Enrolled - 6 - LRB103 30054 BMS 56477 b
	178	+	1 (2) the retail price of the drug in the absence of
	179	+	2 prescription drug coverage.
	180	+	3 (f) Unless required by law, a contract between a pharmacy
	181	+	4 benefit manager or third-party payer and a 340B entity or 340B
	182	+	5 pharmacy shall not contain any provision that:
	183	+	6 (1) distinguishes between drugs purchased through the
	184	+	7 340B drug discount program and other drugs when
	185	+	8 determining reimbursement or reimbursement methodologies,
	186	+	9 or contains otherwise less favorable payment terms or
	187	+	10 reimbursement methodologies for 340B entities or 340B
	188	+	11 pharmacies when compared to similarly situated non-340B
	189	+	12 entities;
	190	+	13 (2) imposes any fee, chargeback, or rate adjustment
	191	+	14 that is not similarly imposed on similarly situated
	192	+	15 pharmacies that are not 340B entities or 340B pharmacies;
	193	+	16 (3) imposes any fee, chargeback, or rate adjustment
	194	+	17 that exceeds the fee, chargeback, or rate adjustment that
	195	+	18 is not similarly imposed on similarly situated pharmacies
	196	+	19 that are not 340B entities or 340B pharmacies;
	197	+	20 (4) prevents or interferes with an individual's choice
	198	+	21 to receive a covered prescription drug from a 340B entity
	199	+	22 or 340B pharmacy through any legally permissible means,
	200	+	23 except that nothing in this paragraph shall prohibit the
	201	+	24 establishment of differing copayments or other
	202	+	25 cost-sharing amounts within the benefit plan for covered
	203	+	26 persons who acquire covered prescription drugs from a
	204	+
	205	+
	206	+
	207	+
	208	+
	209	+	HB3631 Enrolled - 6 - LRB103 30054 BMS 56477 b
	210	+
	211	+
	212	+	HB3631 Enrolled- 7 -LRB103 30054 BMS 56477 b HB3631 Enrolled - 7 - LRB103 30054 BMS 56477 b
	213	+	HB3631 Enrolled - 7 - LRB103 30054 BMS 56477 b
	214	+	1 nonpreferred or nonparticipating provider;
	215	+	2 (5) excludes a 340B entity or 340B pharmacy from a
	216	+	3 pharmacy network on any basis that includes consideration
	217	+	4 of whether the 340B entity or 340B pharmacy participates
	218	+	5 in the 340B drug discount program;
	219	+	6 (6) prevents a 340B entity or 340B pharmacy from using
	220	+	7 a drug purchased under the 340B drug discount program; or
	221	+	8 (7) any other provision that discriminates against a
	222	+	9 340B entity or 340B pharmacy by treating the 340B entity
	223	+	10 or 340B pharmacy differently than non-340B entities or
	224	+	11 non-340B pharmacies for any reason relating to the
	225	+	12 entity's participation in the 340B drug discount program.
	226	+	13 As used in this subsection, "pharmacy benefit manager" and
	227	+	14 "third-party payer" do not include pharmacy benefit managers
	228	+	15 and third-party payers acting on behalf of a Medicaid program.
	229	+	16 (g) A violation of this Section by a pharmacy benefit
	230	+	17 manager constitutes an unfair or deceptive act or practice in
	231	+	18 the business of insurance under Section 424.
	232	+	19 (h) A provision that violates subsection (f) in a contract
	233	+	20 between a pharmacy benefit manager or a third-party payer and
	234	+	21 a 340B entity that is entered into, amended, or renewed after
	235	+	22 July 1, 2022 shall be void and unenforceable.
	236	+	23 (i)(1) A pharmacy benefit manager may not retaliate
	237	+	24 against a pharmacist or pharmacy for disclosing information in
	238	+	25 a court, in an administrative hearing, before a legislative
	239	+	26 commission or committee, or in any other proceeding, if the
	240	+
	241	+
	242	+
	243	+
	244	+
	245	+	HB3631 Enrolled - 7 - LRB103 30054 BMS 56477 b
	246	+
	247	+
	248	+	HB3631 Enrolled- 8 -LRB103 30054 BMS 56477 b HB3631 Enrolled - 8 - LRB103 30054 BMS 56477 b
	249	+	HB3631 Enrolled - 8 - LRB103 30054 BMS 56477 b
	250	+	1 pharmacist or pharmacy has reasonable cause to believe that
	251	+	2 the disclosed information is evidence of a violation of a
	252	+	3 State or federal law, rule, or regulation.
	253	+	4 (2) A pharmacy benefit manager may not retaliate against a
	254	+	5 pharmacist or pharmacy for disclosing information to a
	255	+	6 government or law enforcement agency, if the pharmacist or
	256	+	7 pharmacy has reasonable cause to believe that the disclosed
	257	+	8 information is evidence of a violation of a State or federal
	258	+	9 law, rule, or regulation.
	259	+	10 (3) A pharmacist or pharmacy shall make commercially
	260	+	11 reasonable efforts to limit the disclosure of confidential and
	261	+	12 proprietary information.
	262	+	13 (4) Retaliatory actions against a pharmacy or pharmacist
	263	+	14 include cancellation of, restriction of, or refusal to renew
	264	+	15 or offer a contract to a pharmacy solely because the pharmacy
	265	+	16 or pharmacist has:
	266	+	17 (A) made disclosures of information that the
	267	+	18 pharmacist or pharmacy has reasonable cause to believe is
	268	+	19 evidence of a violation of a State or federal law, rule, or
	269	+	20 regulation;
	270	+	21 (B) filed complaints with the plan or pharmacy benefit
	271	+	22 manager; or
	272	+	23 (C) filed complaints against the plan or pharmacy
	273	+	24 benefit manager with the Department.
	274	+	25 (j) (i) This Section applies to contracts entered into or
	275	+	26 renewed on or after July 1, 2022.
	276	+
	277	+
	278	+
	279	+
	280	+
	281	+	HB3631 Enrolled - 8 - LRB103 30054 BMS 56477 b
	282	+
	283	+
	284	+	HB3631 Enrolled- 9 -LRB103 30054 BMS 56477 b HB3631 Enrolled - 9 - LRB103 30054 BMS 56477 b
	285	+	HB3631 Enrolled - 9 - LRB103 30054 BMS 56477 b
	286	+	1 (k) (j) This Section applies to any group or individual
	287	+	2 policy of accident and health insurance or managed care plan
	288	+	3 that provides coverage for prescription drugs and that is
	289	+	4 amended, delivered, issued, or renewed on or after July 1,
	290	+	5 2020.
	291	+	6 (Source: P.A. 101-452, eff. 1-1-20; 102-778, eff. 7-1-22;
	292	+	7 revised 8-19-22.)
	293	+
	294	+
	295	+
	296	+
	297	+
	298	+	HB3631 Enrolled - 9 - LRB103 30054 BMS 56477 b